Impact of conversion from pegylated interferon-α2b to interferon-α2a for treating recurrent hepatitis C after liver transplantation.
Ikegami TShirabe KYoshizumi TFurusyo NKotoh KKato MShimoda SSoejima YMotomura TFukuhara TMaehara Y
Transplantation
0041-1337
10.1097/TP.0b013e318283a82e
https://doi.org/10.1097/TP.0b013e318283a82ehttps://www.ncbi.nlm.nih.gov/pubmed/23507656